News Announcement

Panacea Biotec: Announcement under Regulation 30 (LODR)-Change in Directorate

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that:

a. Mr. Shantanu Yeshwant Nalavadi has been appointed as an Additional Director of the Company (in the capacity of Non-Executive Director) with effect from December 10 2019. He is not related to any Director of the Company. Brief profile of Mr. Shantanu Yeshwant Nalavadi is enclosed herewith as Annexure - A.

In accordance with the circular dated June 20 2018 issued by the Stock Exchanges we have got the confirmation from Mr. Shantanu Yeshwant Nalavadi that he is not debarred from accessing the capital market and / or restrained from holding the office of Director by virtue of any SEBI Order or any other such authority.

b. Mr. Nithin Krishna Kaimal Non-Executive Director of the Company has resigned from the directorship of the Company with effect from December 10 2019.

You are requested to take the above information on record.

Ask Value Research aks value research information

No question is too small. Share your queries on personal finance, mutual funds, or stocks and let us simplify things for you.


Informed fund ideas, better judgment. Every month. Mutual Fund Insight, every month since October 2002.

Take charge. Know more. Keep more. Mutual Fund Insight helps you do all three — every month